N/A N=93 Rapid, Onsite COVID-19 Detection
COVID-19 · Sars-CoV2
Primary: Number of Samples Tested — 3692 samples
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=61 COVID-19 Screening Program
COVID-19
Primary: Use of a Voluntary COVID-19 Point of Care (POC) Screening Program — 238 total completed screening tests reported
N/A N=99 COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
Sars-CoV-2 Infection · COVID-19
Primary: 30 Candidate Ag Test Self-collections — 53; 0 Participants
N/A N=2,778 You and Me COVID Free
COVID-19
Primary: Main Reason for Testing for COVID-19 — 1632; 493; 238; 343 Participants
N/A N=3 COVID-19 Close Contact Self-Testing Study
Covid19
Primary: Number of Positive Contacts — 0; 0 Participants
N/A N=332 COVID-19 MP Biomedicals SARS-CoV-2 Ag OTC: Clinical Evaluation
SARS-CoV2 Infection · COVID-19
Primary: Positive Percent Agreement — 53; 2 Participants
N/A N=792 COVID-19 Self-Testing Through Rapid Network Distribution
Covid19
Primary: Network Contact Test Uptake — 5; 2 Participants — p=0.45
N/A N=30 Home Usability Study of the SARS-CoV-2 (COVID-19) Test
COVID-19
Primary: Valid SARS-CoV-2 Test — 30 Participants
N/A N=205 Creating a Sustainable Infrastructure for SARS-CoV-2 Testing (COVID-19) at Syringe Exchange Programs
Health Behavior
Primary: Individual Participation in COVID-19 Testing — 25; 21 Participants — p=.6298
N/A N=151 COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With Salivette® Cortisol for Viral RNA Sampling for RT-qPCR
Covid-19
Primary: Number of Participants Testing Positive or Negative for SARS-CoV-2 Virus From Swab and Saliva Samples - Processed in Mexico — 85; 13; 66; 89 Participants
N/A N=464 Repeat Testing for SARS-CoV-2
COVID-19 · Sars-CoV-2
Primary: Number of Participant Phone Surveys Conducted — 3 phone surveys
N/A N=330 Evaluation of Point-of-Care (EPOC) for COVID-19
COVID-19 · SARS CoV 2 Infection
Primary: Test Results Comparison Between LumiraDx and GenScript — 0.097 Unitless
N/A N=877 Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation
COVID-19
Primary: Number of Participants With Positive Results on Both the Q-POC SARS-CoV-2 Assay and the RT-PCR Comparator Test — 130 Participants
N/A N=129 NOWDx Test for the Detection of Antibodies to COVID-19
COVID-19 · SARS-CoV-2 · Coronavirus
Primary: Percentage of Clinical Agreement Between NOWDx COVID-19 Test and Emergency Use Authorized or FDA Cleared Comparator. — 91.5; 95.4 percentage of results matching PCR
N/A N=353 Rapid Turnaround, Home-based Saliva Testing for COVID-19
Covid19
Primary: Number of Matched Test Colormetric Interpretation as a Measure of Interrater Reliability — 52; 69; 97; 27 Completed tests
N/A N=338 Rapid Acceleration for Diagnostics in Underserved Populations: Home Testing
COVID-19
Primary: Number of Participants Who Reported Not Following Social Distancing Guidelines — 164 Participants
N/A N=282 Clinical Performance Evaluation of the Bio-Self™ COVID-19 Antigen Home Test
COVID-19
Primary: Positive Percent Agreement - Sensitivity — 96.2 percent probability
N/A N=668 Optimization of a New Adaptive Intervention to Increase COVID-19 Testing
COVID-19 Testing
Primary: Stage 1: Completion of COVID-19 Test After First Randomization — 78; 71; 0; 0 participants
N/A N=831 Community Collaboration to Combat COVID-19 (C-FORWARD)
Coronavirus Infection
Primary: Uptake of SARS-CoV-2 Testing as Assessed by Proportion of Participants Who Complete Testing — 199; 205; 218; 78 Participants — p=0.67
N/A N=40 Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic
COVID19
Primary: Number of Subjects for Which the Prototype Swab and the Control Swab Provide the Same COVID-19 PCR Result — 18; 17; 22; 23 participants
N/A N=34 MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study
COVID-19 · Influenza A · Influenza B
Primary: Usability of Quick Reference Instructions (QRI) - Critical Steps — 34; 34; 34; 34 participants
N/A N=10 Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing
SARS-CoV2 Infection
Primary: Dental Health Care Worker (DHCW) Willingness to Participate in the Study — 10 Participants
N/A N=1,361 Performance Evaluation of the Lucira COVID-19 & Flu Test
COVID-19 · Influenza
Primary: Confirmation That the Lucira COVID-19 & Flu Test Provides Similar Performance to a High Complexity Lab Molecular Diagnostic RT-PCR Assay(s) With Known High Sensitivity…
N/A N=11 Rutgers Pilot for PREDICT- Patient LAB Test
SARS-CoV2 Infection
Primary: Patient Willingness to Participate in the Study — 30 percentage
N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants
N/A N=14 Rutgers Pilot for PREDICT- Patient POC Test
SARS CoV 2 Infection
Primary: Patient Willingness to Follow Through With the Study Surveys, Triage and Testing — 71.42 percentage of participants
N/A N=102 Evaluating Public Health Interventions to Improve COVID-19 Testing Among Underserved Populations
COVID-19
Primary: Recommended Testing Proportion — 0.66 proportion of times tested asrecommended
N/A N=614 SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings
SARS-CoV-2 Infection · Influenza A · Influenza B
Primary: Qualitative Detection of RNA From SARS-CoV-2, Influenza A, and Influenza B ; Positive Percent Agreement Performance Comparison of Candidate Device (Metrix) vs…
N/A N=554 COVID-19 Treatment Cascade Optimization Study
COVID-19
Primary: Completion of COVID-19 Test — 72; 60 Participants
N/A N=185 Study Utilizing BIOZEK COVID-19 Antigen Rapid Test
Covid-19 Testing
Primary: Sensitivity and Specificity of Biozek Covid-19 Antigen Rapid Test (Saliva) — 97.5; 100 percentage - Sensitivity and specificity